Amphastar Pharmaceuticals, through its wholly owned UK subsidiary, Amphastar UK Limited, acquired a UK-based corporation, International Medication Systems (UK) Limited, including its product trademarks, and other related product assets, as well as marketing authorizations for thirty-three products in the UK, Ireland, Australia, and New Zealand, representing eleven different injectable chemical entities, from UCB Pharma GmbH for $7.7 million. The products are generic injectables containing the following active ingredients: adrenaline, amiodarone, atropine, calcium chloride, furosemide, glucose, lidocaine, magnesium sulphate, morphine, naloxone and sodium bicarbonate. Amphastar plans to transfer the products to its facilities in California. The transfer will require UK MHRA and other related regulatory agency approval before the products can be re-launched.

“We are very happy to be able to expand our presence into the international market with this transaction and to reunite the UK IMS entity with the US IMS entity,” said Jack Zhang, chief executive officer, Amphastar.